Last reviewed · How we verify
OH2 oncolytic virus
At a glance
| Generic name | OH2 oncolytic virus |
|---|---|
| Sponsor | Taizhou HoudeAoke Biomedical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer (PHASE2)
- OH2 Injection in Solid Tumors (PHASE1, PHASE2)
- OH2 Oncolytic Viral Therapy in Central Nervous System Tumors (PHASE1, PHASE2)
- OH2 Injection in Melanoma (PHASE3)
- OH2 Injection in Combination With HX008 for Melanoma. (PHASE1, PHASE2)
- OH2 Administered by Intratumoral Injection (PHASE1)
- OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer (PHASE1)
- OH2 Oncolytic Viral Therapy in Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |